TY - JOUR
T1 - New promising drug targets in cancer- and mtastasis-initiating cells
AU - Mimeault, Murielle
AU - Batra, Surinder K.
PY - 2010/5
Y1 - 2010/5
N2 - The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutictreatments against highly aggressive, metastatic, recurrent, and lethal cancers.
AB - The unique properties of cancer- and metastasis-initiating cells endowed with a high self-renewal and aberrant differentiation potential (including their elevated expression levels of anti-apoptotic factors, multidrug transporters, and DNA repair and detoxifying enzymes) might be associated with their resistance to current clinical cancer therapies and disease recurrence. The eradication of cancer- and metastasis-initiating cells by molecular targeting of distinct deregulated signaling elements that might contribute to their sustained growth, survival, and treatment resistance, therefore, is of immense therapeutic interest. These novel targeted approaches should improve the efficacy of current therapeutictreatments against highly aggressive, metastatic, recurrent, and lethal cancers.
UR - http://www.scopus.com/inward/record.url?scp=77950853025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950853025&partnerID=8YFLogxK
U2 - 10.1016/j.drudis.2010.03.009
DO - 10.1016/j.drudis.2010.03.009
M3 - Review article
C2 - 20338259
AN - SCOPUS:77950853025
SN - 1359-6446
VL - 15
SP - 354
EP - 364
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 9-10
ER -